Virogin aims to be a global, best-in-class oncolytic virus company that creates impactful drugs for patients of the highest medical need.


Our mission is to develop the next generation oncolytic virotherapies to enhance the systemic antitumor immunity.


Source: Gujar et. al. Trends in Immunology, 2017

Our platform technology focuses on creating long-lasting antitumor immunity by capitalizing on a robust, transient antiviral response.

Learn About Our Technology

Led by our leadership team with over 25 years of experience in fundamental research, translational and clinical development of immunotherapy & oncolytic virotherapy, we are determined to bring our novel therapies to market for patients with hard-to-treat cancers.

Meet Our Leadership Team